Naphthylpropylaminopentane

Pharmaceutical compound From Wikipedia, the free encyclopedia

1-(2-Naphthyl)-2-propylaminopentane (NPAP), also known as 2-naphthyl-α,N-dipropylphenethylamine, is a monoaminergic activity enhancer (MAE) of the α-propylphenethylamine and naphthylaminopropane families related to phenylpropylaminopentane (PPAP).[1] It is the analogue of PPAP in which the phenyl ring has been replaced with a naphthalene ring.[1] MAEs are agents that enhance the action potential-mediated release of monoamine neurotransmitters.[2][3][4] NPAP is a MAE of norepinephrine and dopamine but not of serotonin.[1] Its potency is similar to that of PPAP.[1] As with PPAP, the (–)-enantiomer of NPAP is more potent as a MAE.[1] Like PPAP, it is inactive as a classical monoamine releasing agent.[1] NPAP was developed by József Knoll and colleagues and was first described in 2001.[1]

Other names1-(2-Naphthyl)-2-propylaminopentane; NPAP; 2-Naphthyl-α,N-dipropylphenethylamine
ATC code
  • None
Quick facts Clinical data, Other names ...
NPAP
Clinical data
Other names1-(2-Naphthyl)-2-propylaminopentane; NPAP; 2-Naphthyl-α,N-dipropylphenethylamine
Drug classMonoaminergic activity enhancer
ATC code
  • None
Identifiers
  • 1-naphthalen-2-yl-N-propylpentan-2-amine
PubChem CID
ChemSpider
Chemical and physical data
FormulaC18H25N
Molar mass255.405 g·mol−1
3D model (JSmol)
  • CCCC(CC1=CC2=CC=CC=C2C=C1)NCCC
  • InChI=1S/C18H25N/c1-3-7-18(19-12-4-2)14-15-10-11-16-8-5-6-9-17(16)13-15/h5-6,8-11,13,18-19H,3-4,7,12,14H2,1-2H3
  • Key:GKNKHAOHVXOYDS-UHFFFAOYSA-N
Close

See also

References

Related Articles

Wikiwand AI